Relmada Therapeutics, Inc. RLMD Restricted stock acquisition consideration
Restricted stock acquisition consideration at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s restricted stock acquisition consideration.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s restricted stock acquisition consideration?
- Relmada Therapeutics, Inc. (RLMD) reported restricted stock acquisition consideration of $905.23K in Q1 2025.
- What does restricted stock acquisition consideration mean?
- The gross value of restricted stock awards granted to employees or directors during the period. This metric highlights the company's reliance on restricted equity as a primary tool for talent retention and long-term incentive alignment.